KEMET Reports Preliminary Fiscal 2018 First Quarte
Post# of 617763
- Pro forma quarterly sales for the Company and TOKIN of $291 million
- GAAP Gross margin of 28.0% up 280 basis points over prior quarter ending March 31, 2017
- GAAP EPS of $3.84 per diluted share and NON-GAAP EPS of $0.33 per diluted share
- Cash Balance of $225.6 million at June 30, 2017
- September 30, 2017 quarter sales forecast of $295 million to $305 million
GREENVILLE, S.C., Aug. 02, 2017 (GLOBE NEWSWIRE) -- KEMET Corporation (the “Company”) (NYSE:KEM), a leading global supplier of passive electronic components, today reported preliminary results for our first fiscal quarter ended June 30, 2017.
Net sales of $274.0 million for the quarter ended June 30, 2017 increased $76.5 million from net sales of $197.5 million for the prior quarter ended March 31, 2017. TOKIN Corporation ("TOKIN") sales included in total revenue from the period April 19, 2017 to June 30, 2017 were $71.4 million. Pro forma sales for the Company and TOKIN as if the acquisition occurred on April 1, 2017 were $291 million. Net sales for the quarter ended June 30, 2017 increased $89.1 million from net sales of $184.9 million for the quarter ended June 30, 2016, driven primarily by TOKIN net sales of $71.4 million.
U.S. GAAP net income was $221.4 million or $3.84 per diluted share for the quarter ended June 30, 2017. This compares to net income of $52.9 million or $0.93 per diluted share for the quarter ended March 31, 2017. For the quarter ended June 30, 2016, the Company reported a net loss of $12.2 million or $0.26 per basic and diluted share. Net income for the quarter ended June 30, 2017 includes a $75.4 million gain from the equity investment in TOKIN for the period from April 1, 2017 to April 18, 2017, primarily related to KEMET's thirty-four percent interest in TOKIN's gain on the sale of its electro-mechanical devices (“EMD”) business. Additionally, as part of the acquisition of TOKIN, KEMET recorded acquisition gains totaling $136.4 million, consisting of the following: a preliminary gain of $72.7 million to mark its thirty-four percent interest in TOKIN to fair value and a $63.7 million preliminary gain on the acquisition of TOKIN for the quarter ended June 30, 2017. The Company continues to evaluate the calculation of acquisition related gains and, as such, these preliminary numbers may change in the future.
Non-U.S. GAAP adjusted net income was $19.2 million or $0.33 per diluted share for the quarter ended June 30, 2017, as compared to non-U.S. GAAP adjusted net income of $7.8 million or $0.14 per diluted share for the quarter ended March 31, 2017. For the quarter ended June 30, 2016, the Company reported non-U.S. GAAP adjusted net income of $3.3 million or $0.06 per diluted share.
“In our first fiscal quarter of this year we completed all three of our key objectives of closing the TOKIN acquisition, refinancing our long-term debt, and the acquisition being accretive out of the starting gate,” stated Per Loof, the Company’s Chief Executive Officer. “We are extremely pleased with the first quarter financial results combining KEMET with TOKIN and the value creation for all of our stakeholders. The work to extract the synergies from the combination is just beginning but is expected to be additive to our financial results this fiscal year,” continued Loof.
Net income (loss) for the quarters ended June 30, 2017, March 31, 2017 and June 30, 2016 includes various items affecting comparability as denoted in the U.S. GAAP to Non-U.S. GAAP reconciliation table included hereafter.
About KEMET
The Company’s common stock is listed on the NYSE under the ticker symbol “KEM” (NYSE:KEM). At the Investor Relations section of our web site at http://www.kemet.com/IR , users may subscribe to KEMET news releases and find additional information about our Company. KEMET applies world class service and quality to deliver industry leading, high performance capacitance solutions to its customers around the world and offers the world’s most complete line of surface mount and through hole capacitor technologies across tantalum, ceramic, film, aluminum, electrolytic, and paper dielectrics. Additional information about KEMET can be found at http://www.kemet.com .
QUIET PERIOD
Beginning October 1, 2017, we will observe a quiet period during which the information provided in this news release and quarterly report on Form 10-Q will no longer constitute our current expectations. During the quiet period, this information should be considered to be historical, applying prior to the quiet period only and not subject to update by management. The quiet period will extend until the day when our next quarterly earnings release is published.
CAUTIONARY STATEMENT ON FORWARD-LOOKING STATEMENTS
Certain statements included herein contain forward-looking statements within the meaning of federal securities laws about the Company’s financial condition and results of operations that are based on management’s current expectations, estimates and projections about the markets, in which the Company operates, as well as management’s beliefs and assumptions. Words such as “expects,” “anticipates,” “believes,” “estimates,” variations of such words and other similar expressions are intended to identify such forward-looking statements. These statements are not guarantees of future performance and involve certain risks, uncertainties and assumptions, which are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed or forecasted in, or implied by, such forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management’s judgment only as of the date hereof. The Company undertakes no obligation to update publicly any of these forward-looking statements to reflect new information, future events or otherwise.
Factors that may cause actual outcomes and results to differ materially from those expressed in, or implied by, these forward-looking statements include, but are not necessarily limited to the following: (i) adverse economic conditions could impact our ability to realize operating plans if the demand for our products declines, and such conditions could adversely affect our liquidity and ability to continue to operate and cause a write down of long-lived assets or goodwill; (ii) an increase in the cost or a decrease in the availability of our principal or single-sourced purchased raw materials; (iii) changes in the competitive environment; (iv) uncertainty of the timing of customer product qualifications in heavily regulated industries; (v) economic, political, or regulatory changes in the countries in which we operate; (vi) difficulties, delays or unexpected costs in completing the restructuring plans; (vii) acquisitions and other strategic transactions expose us to a variety of risks; (viii) acquisition of TOKIN may not achieve all of the anticipated results; (ix) our business could be negatively impacted by increased regulatory scrutiny and litigation; (x) difficulties associated with retaining, attracting and training effective employees and management; (xi) the need to develop innovative products to maintain customer relationships and offset potential price erosion in older products; (xii) exposure to claims alleging product defects; (xiii) the impact of laws and regulations that apply to our business, including those relating to environmental matters; (xiv) the impact of international laws relating to trade, export controls and foreign corrupt practices; (xv) changes impacting international trade and corporate tax provisions related to the global manufacturing and sales of our products may have an adverse effect on our financial condition and results of operations; (xvi) volatility of financial and credit markets affecting our access to capital; (xvii) the need to reduce the total costs of our products to remain competitive; (xviii) potential limitation on the use of net operating losses to offset possible future taxable income; (xix) restrictions in our debt agreements that could limit our flexibility in operating our business; (xx) disruption to our information technology systems to function properly or control unauthorized access to our systems may cause business disruptions; (xxi) additional exercise of the warrant by K Equity, LLC which could potentially result in the existence of a significant stockholder who could seek to influence our corporate decisions; (xxii) fluctuation in distributor sales could adversely affect our results of operations, (xxiii) earthquakes and other natural disasters could disrupt our operations and have a material adverse effect on our financial condition and results of operations.
Our acquisition accounting, including the acquisition gains, are preliminary as management continues to evaluate the fair value of the net assets acquired and consideration transferred. In addition, the allocation of the purchase price is based on estimates and assumption that are subject to change with the measurement period.
KEMET CORPORATION AND SUBSIDIARIES Condensed Consolidated Statements of Operations (Amounts in thousands, except per share data) (Unaudited) | |||||||
Quarters Ended June 30, | |||||||
2017 | 2016 | ||||||
Net sales | $ | 274,000 | $ | 184,935 | |||
Operating costs and expenses: | |||||||
Cost of sales | 197,324 | 142,412 | |||||
Selling, general and administrative expenses | 37,870 | 25,914 | |||||
Research and development | 9,390 | 6,932 | |||||
Restructuring charges | 1,613 | 688 | |||||
Net (gain) loss on sales and disposals of assets | 19 | 91 | |||||
Total operating costs and expenses | 246,216 | 176,037 | |||||
Operating income (loss) | 27,784 | 8,898 | |||||
Non-operating (income) expense: | |||||||
Interest income | (66 | ) | (3 | ) | |||
Interest expense | 10,960 | 9,923 | |||||
Acquisition gains | (136,386 | ) | — | ||||
Change in value of TOKIN option | — | 12,000 | |||||
Other (income) expense, net | 6,139 | (2,394 | ) | ||||
Income (loss) before income taxes and equity income (loss) from TOKIN | 147,137 | (10,628 | ) | ||||
Income tax expense (benefit) | 1,150 | 1,800 | |||||
Income (loss) before equity income (loss) from TOKIN | 145,987 | (12,428 | ) | ||||
Equity income (loss) from equity method investments | 75,417 | 223 | |||||
Net income (loss) | $ | 221,404 | $ | (12,205 | ) | ||
Net income (loss) per basic share | $ | 4.67 | $ | (0.26 | ) | ||
Net income (loss) per diluted share | $ | 3.84 | $ | (0.26 | ) | ||
Weighted-average shares outstanding: | |||||||
Basic | 47,381 | 46,349 | |||||
Diluted | 57,731 | 46,349 |
KEMET CORPORATION AND SUBSIDIARIES Condensed Consolidated Balance Sheets (Amounts in thousands, except per share data) (Unaudited) | |||||||
June 30, 2017 | March 31, 2017 | ||||||
ASSETS | |||||||
Current assets: | |||||||
Cash and cash equivalents | $ | 225,644 | $ | 109,774 | |||
Accounts receivable, net | 137,562 | 92,526 | |||||
Inventories, net | 192,030 | 147,955 | |||||
Prepaid expenses and other (1) | 51,773 | 28,782 | |||||
Total current assets | 607,009 | 379,037 | |||||
Property, plant and equipment, net of accumulated depreciation of $1,345,781 and $821,276 as of June 30, 2017 and March 31, 2017, respectively | 368,417 | 209,311 | |||||
Goodwill | 40,294 | 40,294 | |||||
Intangible assets, net | 63,664 | 29,781 | |||||
Equity method investments | 12,038 | 63,416 | |||||
Deferred income taxes (1) | 10,528 | 8,367 | |||||
Other assets | 10,002 | 4,119 | |||||
Total assets (1) | $ | 1,111,952 | $ | 734,325 | |||
LIABILITIES AND STOCKHOLDERS’ EQUITY | |||||||
Current liabilities: | |||||||
Current portion of long-term debt | $ | 20,376 | $ | 2,000 | |||
Accounts payable | 135,474 | 69,674 | |||||
Accrued expenses | 88,872 | 57,752 | |||||
Income taxes payable | 531 | 715 | |||||
Total current liabilities | 245,253 | 130,141 | |||||
Long-term debt, less current portion | 315,224 | 386,211 | |||||
Other non-current obligations | 152,073 | 60,131 | |||||
Deferred income taxes (1) | 12,897 | 3,370 | |||||
Stockholders’ equity: | |||||||
Preferred stock, par value $0.01, authorized 10,000 shares, none issued | — | — | |||||
Common stock, par value $0.01, authorized 175,000 shares, issued 47,588 and 46,689 shares at June 30, 2017 and March 31, 2017, respectively | 476 | 467 | |||||
Additional paid-in capital | 447,145 | 447,671 | |||||
Retained deficit (1) | (30,103 | ) | (251,854 | ) | |||
Accumulated other comprehensive income | (31,013 | ) | (41,812 | ) | |||
Total stockholders’ equity | 386,505 | 154,472 | |||||
Total liabilities and stockholders’ equity (1) | $ | 1,111,952 | $ | 734,325 |
(1) March 31, 2017 adjusted due to the adoption of Accounting Standards Update ("ASU") No. 2016-16, Income Taxes - Intra-Entity Transfers of Assets Other Than Inventory
KEMET CORPORATION AND SUBSIDIARIES Condensed Consolidated Statements of Cash Flows (Amounts in thousands) (Unaudited) | |||||||
Quarters Ended June 30, | |||||||
2017 | 2016 | ||||||
Net income (loss) | $ | 221,404 | $ | (12,205 | ) | ||
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: | |||||||
Depreciation and amortization | 12,243 | 9,436 | |||||
Equity (income) loss from TOKIN | (75,417 | ) | (223 | ) | |||
Acquisition gains | (136,386 | ) | — | ||||
Non-cash debt and financing costs | 460 | 190 | |||||
(Gain) loss on early extinguishment of debt | 486 | — | |||||
Stock-based compensation expense | 1,101 | 1,228 | |||||
Change in value of TOKIN option | (9,900 | ) | 12,000 | ||||
Net (gain) loss on sales and disposals of assets | 19 | 91 | |||||
Pension and other post-retirement benefits | 687 | 709 | |||||
Change in deferred income taxes | (129 | ) | 1,294 | ||||
Change in operating assets | 27,986 | (2,357 | ) | ||||
Change in operating liabilities | (34,672 | ) | (13,088 | ) | |||
Other | 467 | (111 | ) | ||||
Net cash provided by (used in) operating activities | 8,349 | (3,036 | ) | ||||
Investing activities: | |||||||
Capital expenditures | (7,298 | ) | (6,167 | ) | |||
Acquisitions, net of cash received | 167,129 | — | |||||
Net cash provided by (used in) investing activities | 159,831 | (6,167 | ) | ||||
Financing activities: | |||||||
Payments on revolving line of credit | (33,881 | ) | — | ||||
Proceeds from issuance of debt | 331,567 | — | |||||
Payments on long-term obligations | (353,000 | ) | (1,870 | ) | |||
Purchase of treasury stock | — | (595 | ) | ||||
Proceeds from exercise of stock options | 2,063 | — | |||||
Net cash provided by (used in) financing activities | (53,251 | ) | (2,465 | ) | |||
Net increase (decrease) in cash and cash equivalents | 114,929 | (11,668 | ) | ||||
Effect of foreign currency fluctuations on cash | 941 | (398 | ) | ||||
Cash and cash equivalents at beginning of fiscal period | 109,774 | 65,004 | |||||
Cash and cash equivalents at end of fiscal period | $ | 225,644 | $ | 52,938 |
Non-U.S. GAAP Financial Measures
The Company utilizes certain Non-U.S. GAAP financial measures, including "Adjusted gross margin", "Adjusted operating income (loss)", “Adjusted net income (loss)”, “Adjusted net income (loss) per share” and “Adjusted EBITDA”. Management believes that investors may find it useful to review the Company’s financial results as adjusted to exclude items as determined by management as further described below.
Adjusted Gross Margin
Adjusted gross margin represents net sales less cost of sales excluding adjustments which are outlined in the quantitative reconciliation provided below. Management uses adjusted gross margin to facilitate our analysis and understanding of our business operations by excluding the items outlined in the quantitative reconciliation provided below which might otherwise make comparisons of our ongoing business with prior periods more difficult and obscure trends in ongoing operations. The Company believes that adjusted gross margin is useful to investors because it provides a supplemental way to understand the underlying operating performance of the Company. Adjusted gross margin should not be considered as an alternative to gross margin or any other performance measure derived in accordance with U.S. GAAP.
The following table provides reconciliation from U.S. GAAP Gross margin to Non-U.S. GAAP adjusted gross margin (amounts in thousands):
Quarters Ended | |||||||||||
(Unaudited) | |||||||||||
June 30, 2017 | March 31, 2017 | June 30, 2016 | |||||||||
Net sales | $ | 274,000 | $ | 197,519 | $ | 184,935 | |||||
Cost of sales | 197,324 | 147,680 | 142,412 | ||||||||
Gross margin (U.S. GAAP) | 76,676 | 49,839 | 42,523 | ||||||||
Gross margin as a % of net sales | 28.0 | % | 25.2 | % | 23.0 | % | |||||
Non-U.S. GAAP adjustments: | |||||||||||
Stock-based compensation expense | 310 | 391 | 384 | ||||||||
Plant start-up costs | — | — | 308 | ||||||||
Adjusted gross margin (non-GAAP) | $ | 76,986 | $ | 50,230 | $ | 43,215 | |||||
Adjusted gross margin as a % of net sales (non-GAAP) | 28.1 | % | 25.4 | % | 23.4 | % |
Adjusted Operating Income (Loss)
Adjusted operating income (loss) represents operating income (loss), excluding adjustments which are outlined in the quantitative reconciliation provided below. Management uses adjusted operating income (loss) to facilitate our analysis and understanding of our business operations by excluding the items outlined in the quantitative reconciliation provided earlier in this presentation which might otherwise make comparisons of our ongoing business with prior periods more difficult and obscure trends in ongoing operations. The Company believes that adjusted operating income (loss) is useful to investors to provide a supplemental way to understand our underlying operating performance and allows investors to monitor and understand changes in our ability to generate income from ongoing business operations. Adjusted operating income (loss) should not be considered as an alternative to operating income (loss) or any other performance measure derived in accordance with U.S. GAAP.
Adjusted operating income (loss) is calculated as follows (amounts in thousands):
Quarters Ended | |||||||||||
(Unaudited) | |||||||||||
June 30, 2017 | March 31, 2017 | June 30, 2016 | |||||||||
Operating income (loss) (U.S. GAAP) | $ | 27,784 | $ | 8,742 | $ | 8,898 | |||||
Adjustments: | |||||||||||
ERP integration/IT transition costs | — | 1,760 | 1,768 | ||||||||
Stock-based compensation expense | 1,101 | 1,249 | 1,228 | ||||||||
Restructuring charges | 1,613 | 1,087 | 688 | ||||||||
Legal expenses related to antitrust class actions | 1,141 | 406 | 1,175 | ||||||||
TOKIN investment-related expenses | — | 497 | 206 | ||||||||
Net (gain) loss on sales and disposals of assets | 19 | 85 | 91 | ||||||||
Write down of long-lived assets | — | 4,086 | — | ||||||||
Plant start-up costs | — | — | 308 | ||||||||
Adjusted operating income (loss) (non-GAAP) | $ | 31,658 | $ | 17,912 | $ | 14,362 |
Adjusted Net Income (Loss) and Adjusted Net Income (Loss) Per Share
“Adjusted net income (loss)” and “Adjusted net income (loss) per basic and diluted share” represent net income (loss) and net income (loss) per basic and diluted share excluding adjustments which are outlined in the quantitative reconciliation provided below. The Company believes that these Non-U.S. GAAP financial measures are useful to investors because they provide a supplemental way to understand the underlying operating performance of the Company and allows investors to monitor and understand changes in our ability to generate income from ongoing business operations. Management uses these Non-U.S. GAAP financial measures to evaluate operating performance by excluding the items outlined in the quantitative reconciliation provided earlier in this presentation which might otherwise make comparisons of our ongoing business with prior periods more difficult and obscure trends in ongoing operations. Non-U.S. GAAP financial measures should not be considered as an alternative to net income, operating income or any other performance measures derived in accordance with U.S. GAAP.
The following table provides reconciliation from U.S. GAAP net income (loss) to Non-U.S. GAAP Adjusted net income (loss) (amounts in thousands):
Quarters Ended | |||||||||||
(Unaudited) | |||||||||||
June 30, 2017 | March 31, 2017 | June 30, 2016 | |||||||||
U.S. GAAP | |||||||||||
Net sales | $ | 274,000 | $ | 197,519 | $ | 184,935 | |||||
Net income (loss) | $ | 221,404 | $ | 52,914 | $ | (12,205 | ) | ||||
Net income (loss) per basic share | $ | 4.67 | $ | 1.13 | $ | (0.26 | ) | ||||
Net income (loss) per diluted share | $ | 3.84 | $ | 0.93 | $ | (0.26 | ) | ||||
Non-U.S. GAAP | |||||||||||
Net income (loss) | $ | 221,404 | $ | 52,914 | $ | (12,205 | ) | ||||
Adjustments: | |||||||||||
Change in value of TOKIN option | — | (14,200 | ) | 12,000 | |||||||
Net foreign exchange (gain) loss | 5,043 | 1,507 | (1,920 | ) | |||||||
ERP integration/IT transition costs | — | 1,760 | 1,768 | ||||||||
Stock-based compensation expense | 1,101 | 1,249 | 1,228 | ||||||||
Restructuring charges | 1,613 | 1,087 | 688 | ||||||||
Legal expenses related to antitrust class actions | 1,141 | 406 | 1,175 | ||||||||
TOKIN investment-related expenses | — | 497 | 206 | ||||||||
Amortization included in interest expense | 460 | 200 | 190 | ||||||||
Acquisition gains | (136,386 | ) | — | — | |||||||
Equity (income) loss from TOKIN | (75,417 | ) | (41,372 | ) | (223 | ) | |||||
Net (gain) loss on sales and disposals of assets | 19 | 85 | 91 | ||||||||
Write down of long-lived assets | — | 4,086 | — | ||||||||
Plant start-up costs | — | — | 308 | ||||||||
(Gain) loss on early extinguishment of debt | 486 | — | — | ||||||||
Income tax effect of non-U.S. GAAP adjustments (1) | (222 | ) | (374 | ) | — | ||||||
Adjusted net income (loss) (non-GAAP) | $ | 19,242 | $ | 7,845 | $ | 3,306 | |||||
Adjusted net income (loss) per basic share (non-GAAP) | $ | 0.41 | $ | 0.17 | $ | 0.07 | |||||
Adjusted net income (loss) per diluted share (non-GAAP) | $ | 0.33 | $ | 0.14 | $ | 0.06 | |||||
Weighted average shares outstanding: | |||||||||||
Weighted average shares-basic | 47,381 | 46,803 | 46,349 | ||||||||
Weighted average shares-diluted | 57,731 | 57,130 | 52,097 |
(1) The income tax effect of the excluded items is calculated by applying the applicable jurisdictional income tax rate, considering the deferred tax valuation for each applicable jurisdiction.
Adjusted EBITDA
Adjusted EBITDA represents net income (loss) before net interest expense, income tax expense (benefit), and depreciation and amortization expense, adjusted to exclude certain items which are outlined in the quantitative reconciliation provided herein. We use adjusted EBITDA to monitor and evaluate our operating performance and to facilitate internal and external comparisons of the historical operating performance of our business. We present adjusted EBITDA as a supplemental measure of our performance and ability to service debt. We also present adjusted EBITDA because we believe such measure is frequently used by securities analysts, investors and other interested parties in the evaluation of companies in our industry.
We believe adjusted EBITDA is an appropriate supplemental measure of debt service capacity, because cash expenditures on interest are, by definition, available to pay interest, and tax expense is inversely correlated to interest expense because tax expense goes down as deductible interest expense goes up; depreciation and amortization are non-cash charges. The other adjustments to arrive at adjusted EBITDA are excluded in order to better reflect our continuing operations.
In evaluating adjusted EBITDA, you should be aware that in the future we may incur expenses similar to the adjustments noted below. Our presentation of adjusted EBITDA should not be construed as an inference that our future results will be unaffected by these types of adjustments. Adjusted EBITDA is not a measurement of our financial performance under U.S. GAAP and should not be considered as an alternative to net income, operating income or any other performance measures derived in accordance with U.S. GAAP or as an alternative to cash flow from operating activities as a measure of our liquidity.
Our adjusted EBITDA measure has limitations as an analytical tool, and should not be considered in isolation or as a substitute for analysis of our results as reported under U.S. GAAP. Some of these limitations are:
- it does not reflect our cash expenditures, future requirements for capital expenditures or contractual commitments;
- it does not reflect changes in, or cash requirements for, our working capital needs;
- it does not reflect the significant interest expense or the cash requirements necessary to service interest or principal payment on our debt;
- although depreciation and amortization are non-cash charges, the assets being depreciated and amortized will often have to be replaced in the future, and our adjusted EBITDA measure does not reflect any cash requirements for such replacements;
- it is not adjusted for all non-cash income or expense items that are reflected in our statements of cash flows;
- it does not reflect the impact of earnings or charges resulting from matters we consider not to be indicative of our ongoing operations;
- it does not reflect limitations on or costs related to transferring earnings from our subsidiaries to us; and
- other companies in our industry may calculate this measure differently than we do, limiting its usefulness as a comparative measure.
Because of these limitations, adjusted EBITDA should not be considered as a measure of discretionary cash available to us to invest in the growth of our business or as a measure of cash that will be available to us to meet our obligations. You should compensate for these limitations by relying primarily on our U.S. GAAP results and using adjusted EBITDA as supplementary information.
The following table provides a reconciliation from U.S. GAAP net income (loss) to Adjusted EBITDA (amounts in thousands):
Quarters Ended | |||||||||||
(Unaudited) | |||||||||||
June 30, 2017 | March 31, 2017 | June 30, 2016 | |||||||||
Net income (loss) (U.S. GAAP) | $ | 221,404 | $ | 52,914 | $ | (12,205 | ) | ||||
Interest expense, net | 10,894 | 9,994 | 9,920 | ||||||||
Income tax expense (benefit) | 1,150 | (150 | ) | 1,800 | |||||||
Depreciation and amortization | 12,243 | 9,367 | 9,436 | ||||||||
EBITDA (non-GAAP) | 245,691 | 72,125 | 8,951 | ||||||||
Excluding the following items: | |||||||||||
Change in value of TOKIN option | — | (14,200 | ) | 12,000 | |||||||
Net foreign exchange (gain) loss | 5,043 | 1,507 | (1,920 | ) | |||||||
Stock-based compensation expense | 1,101 | 1,249 | 1,228 | ||||||||
ERP integration/IT transition costs | — | 1,760 | 1,768 | ||||||||
Restructuring charges | 1,613 | 1,087 | 688 | ||||||||
Legal expenses related to antitrust class actions | 1,141 | 406 | 1,175 | ||||||||
TOKIN investment-related expenses | — | 497 | 206 | ||||||||
Acquisition gains | (136,386 | ) | — | — | |||||||
Equity (income) loss from NEC TOKIN | (75,417 | ) | (41,372 | ) | (223 | ) | |||||
(Gain) loss on early extinguishment of debt | 486 | — | — | ||||||||
Net (gain) loss on sales and disposals of assets | 19 | 85 | 91 | ||||||||
Plant start-up costs | — | — | 308 | ||||||||
Write down of long-lived assets | — | 4,086 | — | ||||||||
Adjusted EBITDA (non-GAAP) | $ | 43,291 | $ | 27,230 | $ | 24,272 |
William M. Lowe, Jr.
Executive Vice President and Chief Financial Officer
williamlowe@kemet.com
864-963-6484
Richard J. Vatinelle
Vice President and Treasurer
richardvatinelle@kemet.com
954-766-2838